PharmaLegacy Laboratories announced on September 16 that it acquired BTS Research, a San Diego, California-based contract research organization (CRO).
BTS Research (formerly BioTox Sciences) delivers GLP and Non-GLP biological services to clients in pharmaceutical, biopharmaceutical, biotech, academic research, medical device and related industries. The CRO was founded in 2007 and acquired Bio-Quant in 2011.
PharmaLegacy Laboratories is a CRO founded in 2008 which provides efficient and cost-effective preclinical in vitro and in vivo pharmacology studies to life science organizations. PharmaLegacy boasts a thousand of validated in vitro and in vivo services across more than 40 different diseases, and has contributed to more than 400 investigational new drug applications.
San Diego is a significant global research and development hub and the acquisition allows PharmaLegacy to join the greater community while also strengthening and expanding PharmaLegacy’s global research capabilities and service offerings. The acquisition of BTS will allow PharmaLegacy to add GLP toxicology services to its complete offering of pharmacology services. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 22nd CRO deal of 2024. There were 44 CRO transactions announced during 2023 and 41 announced during 2022.
